Literature DB >> 7691145

Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer.

T Uchida1, C Wada, T Shitara, S Egawa, K Koshiba.   

Abstract

A study was made of the incidence of p53 mutations in Japanese males with prostate cancer or benign prostatic hyperplasia. Polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) was used as a primary screening technique with gene sequencing being carried out in positive cases. Two out of 21 prostate cancers (9.5%) were found to have p53 mutations. These were stage B2 and D2 prostate cancers. No abnormalities were found in the remaining cases or benign prostatic hyperplasia. Mutations of the p53 gene would thus appear infrequent in the tumourigenesis of primary prostate cancer.

Entities:  

Mesh:

Year:  1993        PMID: 7691145      PMCID: PMC1968625          DOI: 10.1038/bjc.1993.423

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  45 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ.

Authors:  T C Thompson; J Southgate; G Kitchener; H Land
Journal:  Cell       Date:  1989-03-24       Impact factor: 41.582

3.  Recessive genetic mechanisms in the oncogenesis of prostatic carcinoma.

Authors:  U S Bergerheim; V P Collins; P Ekman; K Kunimi
Journal:  Scand J Urol Nephrol Suppl       Date:  1991

4.  Isolation of a human prostate carcinoma cell line (DU 145).

Authors:  K R Stone; D D Mickey; H Wunderli; G H Mickey; D F Paulson
Journal:  Int J Cancer       Date:  1978-03-15       Impact factor: 7.396

5.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

6.  p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases.

Authors:  Y Yamada; T Yoshida; K Hayashi; T Sekiya; J Yokota; S Hirohashi; K Nakatani; H Nakano; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

7.  Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas.

Authors:  K Anwar; K Nakakuki; T Shiraishi; H Naiki; R Yatani; M Inuzuka
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

8.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3).

Authors:  M E Kaighn; K S Narayan; Y Ohnuki; J F Lechner; L W Jones
Journal:  Invest Urol       Date:  1979-07

9.  P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia.

Authors:  S J Thompson; K Mellon; R G Charlton; C Marsh; M Robinson; D E Neal
Journal:  Br J Urol       Date:  1992-06

10.  Alterations of the P53 gene are associated with the progression of a human prostate carcinoma.

Authors:  P J Effert; A Neubauer; P J Walther; E T Liu
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

View more
  9 in total

Review 1.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

Authors:  J T Isaacs
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

3.  PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.

Authors:  F Kimura; J Watanabe; H Hata; T Fujisawa; Y Kamata; Y Nishimura; T Jobo; H Kuramoto
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-20       Impact factor: 4.553

4.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; H Matsuda; M Tao; T Tsuzuki; I Hayashi; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

5.  Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.

Authors:  D Mirchandani; J Zheng; G J Miller; A K Ghosh; D K Shibata; R J Cote; P Roy-Burman
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

6.  Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker.

Authors:  S J Chia; W Y Tang; J Elnatan; W M Yap; H S Goh; D R Smith
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

7.  A microdissection approach to detect molecular markers during progression of prostate cancer.

Authors:  P Berthon; T Dimitrov; M Stower; O Cussenot; N J Maitland
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

8.  p53 gene mutations in human prostate cancers in Japan: different mutation spectra between Japan and western countries.

Authors:  M Watanabe; T Ushijima; H Kakiuchi; T Shiraishi; R Yatani; J Shimazaki; T Kotake; T Sugimura; M Nagao
Journal:  Jpn J Cancer Res       Date:  1994-09

9.  p53 mutations occur in clinical, but not latent, human prostate carcinoma.

Authors:  N Konishi; Y Hiasa; I Hayashi; H Matsuda; T Tsuzuki; T Ming; Y Kitahori; T Shiraishi; R Yatani; J Shimazaki
Journal:  Jpn J Cancer Res       Date:  1995-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.